

2017-2022 Global and Japan Antitumor Drugs of Antimetabolite Class Market Analysis Report

<https://marketpublishers.com/r/2A8452B83F2EN.html>

Date: August 2017

Pages: 111

Price: US\$ 3,085.00 (Single User License)

ID: 2A8452B83F2EN

Abstracts

The global Antitumor Drugs of Antimetabolite Class market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022.

Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%.

This report, with focus on top players in the global and Japan, studies the Antitumor Drugs of Antimetabolite Class market's development status and future trend in the global and Japan. It splits Antitumor Drugs of Antimetabolite Class market by type and by applications to fully and deeply research and reveal market profile and prospect.

The major players include

AYUMI Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

Kyowa Hakko Kirin Co.,Ltd

Mitsubishi Tanabe Pharma Corporation

Nichi-iko Pharmaceutical Co.,Ltd

Novartis Pharma K.K.

Pfizer Pharmaceuticals Inc.

POLA PHARMA INC.

Sawai Pharmaceutical Co.,Ltd.

TOWA PHARMACEUTICAL CO., LTD.

TAIHO Pharmaceutical Co.,LTD.

Elmed Eisai Co., Ltd.

NIPRO CORPORATION

NIPPON KAYAKU

Meiji Seika Pharma Co., Ltd.

OKAYAMA TAIHO Pharmaceutical Co., Ltd.

Geographically, this report splits the Global market into the following regions:

Asia Pacific

Japan

Tokyo

Yokohama

Osaka

Nagoya

Others

China

Korea

India

Others

Europe

France

Germany

United Kingdom

Italy

Russia

Others

North America

United States

Canada

Latin America

Brazil

Mexico

Others

Southeast Asia

Singapore

Malaysia

Vietnam

Myanmar

Thailand

Indonesia

Philippines

Others

Middle East & Africa

Saudi Arabia

Iran

UAE

Turkey

Israel

Egypt

South Africa

Others

On the basis of product, the Antitumor Drugs of Antimetabolite Class market is primarily split into

Antitumor Drugs of Antimetabolite Class Market, by Antimetabolite Class

Gemcitabine

Doxifluridine

Methotrexate

Cytarabine

Fludarabine

Vinorelbine

Temozolomide

Clofarabine

Arranon

Ciclosporin

Tegafur

Aminopterin

Key Applications

Oncology Department

Department of Chemotherapy

Pharmacology

Contents

1 ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS OVERVIEW

- 1.1 Product Overview and Scope of Antitumor Drugs of Antimetabolite Class
- 1.2 Global and Japan Antitumor Drugs of Antimetabolite Class Market by Applications/End Users
 - 1.2.1 Japan Antitumor Drugs of Antimetabolite Class Sales () and Market Share Comparison by Applications (2012-2017)
 - 1.2.1.1 Japan Antitumor Drugs of Antimetabolite Class Sales () and Market Share by Applications (2012-2017)
 - 1.2.1.2 Japan Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) by Applications (2012-2017)
 - 1.2.1.3 Market Drivers and Opportunities
 - 1.2.2 Japan Antitumor Drugs of Antimetabolite Class Sales () and Market Share Comparison by Applications (2012-2017)
 - 1.2.3 Global Antitumor Drugs of Antimetabolite Class Sales by Application (2012-2017)
 - 1.2.3.1 Global Antitumor Drugs of Antimetabolite Class Sales () and Market Share by Applications (2012-2017)
 - 1.2.3.2 Global Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) by Applications (2012-2017)
 - 1.2.3.3 Market Drivers and Opportunities
 - 1.2.4 Global Antitumor Drugs of Antimetabolite Class Sales () and Market Share Comparison by Applications (2012-2017)
 - 1.2.5 Oncology Department
 - 1.2.6 Department of Chemotherapy
 - 1.2.7 Pharmacology
- 1.3 Global and Japan Market Size (Sales and Revenue) of Antitumor Drugs of Antimetabolite Class (2012-2017)
 - 1.3.1 Japan Market Size (Sales and Revenue) of Antitumor Drugs of Antimetabolite Class (2012-2017)
 - 1.3.1.1 Japan Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (%) (2012-2017)
 - 1.3.1.2 Japan Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate (2012-2017)
 - 1.3.2 Global Market Size (Sales and Revenue) of Antitumor Drugs of Antimetabolite Class (2012-2017)
 - 1.3.2.1 Global Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (%) (2012-2017)

1.3.2.2 Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate (2012-2017)

1.4 Global and Japan Classification of Antitumor Drugs of Antimetabolite Class by Antimetabolite Class

1.4.1 Japan Antitumor Drugs of Antimetabolite Class Sales () and Market Share by Antimetabolite Class (2012-2017)

1.4.2 Global Antitumor Drugs of Antimetabolite Class Sales () and Market Share by Antimetabolite Class (2012-2017)

1.4.3 Japan Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share by Antimetabolite Class (2012-2017)

1.4.4 Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share by Antimetabolite Class (2012-2017)

1.4.5 Japan Antitumor Drugs of Antimetabolite Class Price () by Antimetabolite Class (2012-2017)

1.4.6 Global Antitumor Drugs of Antimetabolite Class Price () by Antimetabolite Class (2012-2017)

1.4.7 Japan Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) by Antimetabolite Class (2012-2017)

1.4.8 Global Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) by Antimetabolite Class (2012-2017)

1.4.9 Gemcitabine

1.4.10 Doxifluridine

1.4.11 Methotrexate

1.4.12 Cytarabine

1.4.13 Fludarabine

Vinorelbine

Temozolomide

Clofarabine

Arranon

Ciclosporin

Tegafur

Aminopterin

2 GLOBAL AND JAPAN ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MARKET COMPETITION BY PLAYERS/MANUFACTURERS

2.1 Japan Antitumor Drugs of Antimetabolite Class Market Competition by Players/Manufacturers

2.1.1 Japan Antitumor Drugs of Antimetabolite Class Sales and Market Share of Key

Players/Manufacturers (2012-2017)

2.1.2 Japan Antitumor Drugs of Antimetabolite Class Revenue and Share by
Players/Manufacturers (2012-2017)

2.1.3 Japan Antitumor Drugs of Antimetabolite Class Average Price () by
Players/Manufacturers (2012-2017)

2.1.4 Japan Antitumor Drugs of Antimetabolite Class Market Competitive Situation and
Trends

2.1.4.1 Japan Antitumor Drugs of Antimetabolite Class Market Concentration Rate

2.1.4.2 Japan Antitumor Drugs of Antimetabolite Class Market Share of Top 3 and
Top 5 Players/Manufacturers

2.1.4.3 Mergers & Acquisitions, Expansion in Japan Market

2.1.5 Japan Players/Manufacturers Antitumor Drugs of Antimetabolite Class
Manufacturing Base Distribution, Sales Area, Product Types

2.2 Global Antitumor Drugs of Antimetabolite Class Market Competition by
Players/Manufacturers

2.2.1 Global Antitumor Drugs of Antimetabolite Class Sales and Market Share of Key
Players/Manufacturers (2012-2017)

2.2.2 Global Antitumor Drugs of Antimetabolite Class Revenue and Share by
Players/Manufacturers (2012-2017)

2.2.3 Global Antitumor Drugs of Antimetabolite Class Average Price () by
Players/Manufacturers (2012-2017)

2.2.4 Global Antitumor Drugs of Antimetabolite Class Market Competitive Situation and
Trends

2.2.4.1 Global Antitumor Drugs of Antimetabolite Class Market Concentration Rate

2.2.4.2 Global Antitumor Drugs of Antimetabolite Class Market Share of Top 3 and
Top 5 Players/Manufacturers

2.2.4.3 Mergers & Acquisitions, Expansion in Global Market

2.2.5 Global Players/Manufacturers Antitumor Drugs of Antimetabolite Class
Manufacturing Base Distribution, Sales Area, Product Types

3 GLOBAL AND JAPAN ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS SALES AND REVENUE BY REGIONS (2012-2017)

3.1 Asia Pacific Antitumor Drugs of Antimetabolite Class Sales and Revenue by
Regions (2012-2017)

3.1.1 Japan Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.1.1.1 Japan Antitumor Drugs of Antimetabolite Class Sales () and Market Share
(2012-2017)

3.1.1.2 Japan Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and

Market Share (2012-2017)

3.1.1.3 Japan Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.1.2 China Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.1.2.1 China Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.1.2.2 China Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.1.2.3 China Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.1.3 Korea Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.1.3.1 Korea Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.1.3.2 Korea Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.1.3.3 Korea Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.1.4 India Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.1.4.1 India Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.1.4.2 India Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.1.4.3 India Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.1.5 Others Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.1.5.1 Others Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.1.5.2 Others Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.1.5.3 Others Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.2 Europe Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)

3.2.1 France Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.2.1.1 France Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.2.1.2 France Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.2.1.3 France Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.2.2 Germany Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.2.2.1 Germany Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.2.2.2 Germany Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and

Market Share (2012-2017)

3.2.2.3 Germany Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.2.3 United Kingdom Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.2.3.1 United Kingdom Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.2.3.2 United Kingdom Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.2.3.3 United Kingdom Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.2.4 Italy Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.2.4.1 Italy Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.2.4.2 Italy Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.2.4.3 Italy Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.2.5 Russia Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.2.5.1 Russia Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.2.5.2 Russia Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.2.5.3 Russia Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.2.6 Others Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.2.6.1 Others Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.2.6.2 Others Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.2.6.3 Others Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.3 North America Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)

3.3.1 United States Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.3.1.1 United States Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share (2012-2017)

3.3.1.2 United States Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.3.1.3 United States Antitumor Drugs of Antimetabolite Class Price (€)(2012-2017)

3.3.2 Canada Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.3.2.1 Canada Antitumor Drugs of Antimetabolite Class Sales (€) and Market Share

(2012-2017)

3.3.2.2 Canada Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.3.2.3 Canada Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.4 Latin America Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)

3.4.1 Brazil Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.4.1.1 Brazil Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.4.1.2 Brazil Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.4.1.3 Brazil Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.4.2 Mexico Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.4.2.1 Mexico Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.4.2.2 Mexico Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.4.2.3 Mexico Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.4.3 Others Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.4.3.1 Others Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.4.3.2 Others Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.4.3.3 Others Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.5 Southeast Asia Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)

3.5.1 Singapore Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.5.1.1 Singapore Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.5.1.2 Singapore Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.5.1.3 Singapore Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.5.2 Malaysia Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.5.2.1 Malaysia Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.5.2.2 Malaysia Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

- 3.5.2.3 Malaysia Antitumor Drugs of Antimetabolite Class Price (2012-2017)
- 3.5.3 Vietnam Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
 - 3.5.3.1 Vietnam Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
 - 3.5.3.2 Vietnam Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.3.3 Vietnam Antitumor Drugs of Antimetabolite Class Price (2012-2017)
- 3.5.4 Myanmar Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
 - 3.5.4.1 Myanmar Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
 - 3.5.4.2 Myanmar Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.4.3 Myanmar Antitumor Drugs of Antimetabolite Class Price (2012-2017)
- 3.5.5 Thailand Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
 - 3.5.5.1 Thailand Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
 - 3.5.5.2 Thailand Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.5.3 Thailand Antitumor Drugs of Antimetabolite Class Price (2012-2017)
- 3.5.6 Indonesia Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
 - 3.5.6.1 Indonesia Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
 - 3.5.6.2 Indonesia Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.6.3 Indonesia Antitumor Drugs of Antimetabolite Class Price (2012-2017)
- 3.5.7 Philippines Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
 - 3.5.7.1 Philippines Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)
 - 3.5.7.2 Philippines Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)
 - 3.5.7.3 Philippines Antitumor Drugs of Antimetabolite Class Price (2012-2017)
- 3.5.8 Others Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)
 - 3.5.8.1 Others Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.5.8.2 Others Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.5.8.3 Others Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.6 Middle East & Africa Antitumor Drugs of Antimetabolite Class Sales and Revenue by Regions (2012-2017)

3.6.1 Saudi Arabia Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.6.1.1 Saudi Arabia Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.6.1.2 Saudi Arabia Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.6.1.3 Saudi Arabia Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.6.2 Iran Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.6.2.1 Iran Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.6.2.2 Iran Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.6.2.3 Iran Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.6.3 UAE Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.6.3.1 UAE Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.6.3.2 UAE Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.6.3.3 UAE Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.6.4 Turkey Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.6.4.1 Turkey Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.6.4.2 Turkey Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.6.4.3 Turkey Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.6.5 Israel Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.6.5.1 Israel Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.6.5.2 Israel Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.6.5.3 Israel Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.6.6 Egypt Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.6.6.1 Egypt Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.6.6.2 Egypt Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.6.6.3 Egypt Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.6.7 South Africa Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.6.7.1 South Africa Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.6.7.2 South Africa Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.6.7.3 South Africa Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

3.6.8 Others Antitumor Drugs of Antimetabolite Class Sales and Revenue (2012-2017)

3.6.8.1 Others Antitumor Drugs of Antimetabolite Class Sales () and Market Share (2012-2017)

3.6.8.2 Others Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Market Share (2012-2017)

3.6.8.3 Others Antitumor Drugs of Antimetabolite Class Price ()(2012-2017)

4 GLOBAL AND JAPAN ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS PLAYERS/MANUFACTURERS PROFILES AND SALES DATA

4.1 AYUMI Pharmaceutical Co., Ltd.

4.1.1 Company Basic Information, Manufacturing Base and Competitors

4.1.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification

4.1.2.1 Product A

4.1.2.2 Product B

4.1.3 AYUMI Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)

4.1.4 Main Business/Business Overview

4.2 Chugai Pharmaceutical Co., Ltd.

4.2.1 Company Basic Information, Manufacturing Base and Competitors

4.2.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification

4.2.2.1 Product A

4.2.2.2 Product B

4.2.3 Chugai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)

4.2.4 Main Business/Business Overview

4.3 Kyowa Hakko Kirin Co.,Ltd

- 4.3.1 Company Basic Information, Manufacturing Base and Competitors
- 4.3.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
 - 4.3.2.1 Product A
 - 4.3.2.2 Product B
- 4.3.3 Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)
- 4.3.4 Main Business/Business Overview
- 4.4 Mitsubishi Tanabe Pharma Corporation
 - 4.4.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.4.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
 - 4.4.2.1 Product A
 - 4.4.2.2 Product B
 - 4.4.3 Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)
 - 4.4.4 Main Business/Business Overview
- 4.5 Nichi-iko Pharmaceutical Co.,Ltd
 - 4.5.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.5.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
 - 4.5.2.1 Product A
 - 4.5.2.2 Product B
 - 4.5.3 Nichi-iko Pharmaceutical Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)
 - 4.5.4 Main Business/Business Overview
- 4.6 Novartis Pharma K.K.
 - 4.6.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.6.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification
 - 4.6.2.1 Product A
 - 4.6.2.2 Product B
 - 4.6.3 Novartis Pharma K.K. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)
 - 4.6.4 Main Business/Business Overview
- 4.7 Pfizer Pharmaceuticals Inc.
 - 4.7.1 Company Basic Information, Manufacturing Base and Competitors
 - 4.7.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification

4.7.2.1 Product A

4.7.2.2 Product B

4.7.3 Pfizer Pharmaceuticals Inc. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

4.7.4 Main Business/Business Overview

4.8 POLA PHARMA INC.

4.8.1 Company Basic Information, Manufacturing Base and Competitors

4.8.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification

4.8.2.1 Product A

4.8.2.2 Product B

4.8.3 POLA PHARMA INC. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

4.8.4 Main Business/Business Overview

4.9 Sawai Pharmaceutical Co., Ltd.

4.9.1 Company Basic Information, Manufacturing Base and Competitors

4.9.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification

4.9.2.1 Product A

4.9.2.2 Product B

4.9.3 Sawai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

4.9.4 Main Business/Business Overview

4.10 TOWA PHARMACEUTICAL CO., LTD.

4.10.1 Company Basic Information, Manufacturing Base and Competitors

4.10.2 Antitumor Drugs of Antimetabolite Class Product Category, Application and Specification

4.10.2.1 Product A

4.10.2.2 Product B

4.10.3 TOWA PHARMACEUTICAL CO., LTD. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

4.10.4 Main Business/Business Overview

4.11 TAIHO Pharmaceutical Co., LTD.

4.12 Elmed Eisai Co., Ltd.

4.13 NIPRO CORPORATION

4.14 NIPPON KAYAKU

4.15 Meiji Seika Pharma Co., Ltd.

4.16 OKAYAMA TAIHO Pharmaceutical Co., Ltd.

5 ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MANUFACTURING COST ANALYSIS

5.1 Antitumor Drugs of Antimetabolite Class Key Raw Materials Analysis

5.1.1 Key Raw Materials

5.1.2 Price Trend of Key Raw Materials

5.1.3 Key Suppliers of Raw Materials

5.1.4 Market Concentration Rate of Raw Materials

5.2 Proportion of Manufacturing Cost Structure

5.2.1 Raw Materials

5.2.2 Labor Cost

5.2.3 Manufacturing Expenses

5.3 Manufacturing Process Analysis of Antitumor Drugs of Antimetabolite Class

6 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

6.1 Antitumor Drugs of Antimetabolite Class Industrial Chain Analysis

6.2 Upstream Raw Materials Sourcing

6.3 Raw Materials Sources of Antitumor Drugs of Antimetabolite Class Major Players/Manufacturers in 2016

6.4 Downstream Buyers

7 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

7.1 Marketing Channel

7.1.1 Direct Marketing

7.1.2 Indirect Marketing

7.1.3 Marketing Channel Development Trend

7.2 Market Positioning

7.2.1 Pricing Strategy

7.2.2 Brand Strategy

7.2.3 Target Client

7.3 Distributors/Traders List

8 MARKET EFFECT FACTORS ANALYSIS

8.1 Technology Progress/Risk

8.1.1 Substitutes Threat

8.1.2 Technology Progress in Related Industry

8.2 Consumer Needs/Customer Preference Change

8.3 Economic/Political Environmental Change

9 GLOBAL AND JAPAN ANTITUMOR DRUGS OF ANTIMETABOLITE CLASS MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)

9.1 Global and Japan Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD) Forecast (2017-2022)

9.2 Global and Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Type (2017-2022)

9.2.1 by Antimetabolite Class

9.2.2 by

9.3 Global and Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)

9.4 Global and Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)

10 RESEARCH FINDINGS AND CONCLUSION

11 METHODOLOGY AND DATA SOURCE

11.1 Methodology/Research Approach

11.1.1 Research Programs/Design

11.1.2 Market Size Estimation

11.1.3 Market Breakdown and Data Triangulation

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Disclaimer

11.4 Author List

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Antitumor Drugs of Antimetabolite Class

Table Japan Antitumor Drugs of Antimetabolite Class Sales (Million Units) Comparison by Applications (2012-2017)

Figure Japan Sales Market Share (%) of Antitumor Drugs of Antimetabolite Class by Applications in 2016

Table Global Antitumor Drugs of Antimetabolite Class Sales (Million Units) Comparison by Applications (2012-2017)

Figure Global Sales Market Share (%) of Antitumor Drugs of Antimetabolite Class by Applications in 2016

Figure Oncology Department Examples

Table Key Downstream Customer in Oncology Department

Figure Department of Chemotherapy Examples

Table Key Downstream Customer in Department of Chemotherapy

Figure Pharmacology Examples

Table Key Downstream Customer in Pharmacology

Figure Gemcitabine Product Picture

Figure Doxifluridine Product Picture

Figure Methotrexate Product Picture

Figure Cytarabine Product Picture

Figure Fludarabine Product Picture

Figure Product Picture

Figure Product Picture

Table AYUMI Pharmaceutical Co., Ltd. Basic Information List

Table AYUMI Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales (Million Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)

Table AYUMI Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) (2012-2017)

Table AYUMI Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)

Figure AYUMI Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)

Table Chugai Pharmaceutical Co., Ltd. Basic Information List

Table Chugai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales (Million Units), Revenue (Million USD), Price (USD) and Gross Margin (%) (2012-2017)

Table Chugai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales

Growth Rate (%)(2012-2017)

Table Chugai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)

Figure Chugai Pharmaceutical Co., Ltd. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)

Table Kyowa Hakko Kirin Co.,Ltd Basic Information List

Table Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)

Table Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)

Table Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)

Figure Kyowa Hakko Kirin Co.,Ltd Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)

Table Mitsubishi Tanabe Pharma Corporation Basic Information List

Table Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)

Table Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)

Table Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)

Figure Mitsubishi Tanabe Pharma Corporation Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)

Table Nichi-iko Pharmaceutical Co.,Ltd Basic Information List

Table Nichi-iko Pharmaceutical Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)

Table Nichi-iko Pharmaceutical Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)

Table Nichi-iko Pharmaceutical Co.,Ltd Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)

Figure Nichi-iko Pharmaceutical Co.,Ltd Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)

Table Novartis Pharma K.K. Basic Information List

Table Novartis Pharma K.K. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%)(2012-2017)

Table Novartis Pharma K.K. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%)(2012-2017)

Table Novartis Pharma K.K. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)

Figure Novartis Pharma K.K. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)

Table Pfizer Pharmaceuticals Inc. Basic Information List

Table Pfizer Pharmaceuticals Inc. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table Pfizer Pharmaceuticals Inc. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) (2012-2017)

Table Pfizer Pharmaceuticals Inc. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)

Figure Pfizer Pharmaceuticals Inc. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)

Table POLA PHARMA INC. Basic Information List

Table POLA PHARMA INC. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table POLA PHARMA INC. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) (2012-2017)

Table POLA PHARMA INC. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)

Figure POLA PHARMA INC. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)

Table Sawai Pharmaceutical Co.,Ltd. Basic Information List

Table Sawai Pharmaceutical Co.,Ltd. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table Sawai Pharmaceutical Co.,Ltd. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) (2012-2017)

Table Sawai Pharmaceutical Co.,Ltd. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)

Figure Sawai Pharmaceutical Co.,Ltd. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)

Table TOWA PHARMACEUTICAL CO., LTD. Basic Information List

Table TOWA PHARMACEUTICAL CO., LTD. Antitumor Drugs of Antimetabolite Class Sales (), Revenue (Million USD), Price () and Gross Margin (%) (2012-2017)

Table TOWA PHARMACEUTICAL CO., LTD. Antitumor Drugs of Antimetabolite Class Sales Growth Rate (%) (2012-2017)

Table TOWA PHARMACEUTICAL CO., LTD. Antitumor Drugs of Antimetabolite Class Sales Market Share (%) in Japan (2012-2017)

Figure TOWA PHARMACEUTICAL CO., LTD. Antitumor Drugs of Antimetabolite Class Revenue Market Share (%) in Japan (2012-2017)

Table TAIHO Pharmaceutical Co.,LTD. Basic Information List

Table Elmed Eisai Co., Ltd. Basic Information List

Table NIPRO CORPORATION Basic Information List

Table NIPPON KAYAKU Basic Information List

Table Meiji Seika Pharma Co., Ltd. Basic Information List

Table OKAYAMA TAIHO Pharmaceutical Co., Ltd. Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Antitumor Drugs of Antimetabolite Class

Figure Manufacturing Process Analysis of Antitumor Drugs of Antimetabolite Class

Figure Antitumor Drugs of Antimetabolite Class Industrial Chain Analysis

Table Raw Materials Sources of Antitumor Drugs of Antimetabolite Class Major Players/Manufacturers in 2016

Table Major Buyers of Antitumor Drugs of Antimetabolite Class

Table Distributors/Traders List

Figure Japan Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (%) Forecast (2017-2022)

Figure Japan Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure Japan Antitumor Drugs of Antimetabolite Class Price () Trend Forecast (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales () and Growth Rate (%) Forecast (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Price () Trend Forecast (2017-2022)

Table Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Type (2017-2022)

Table Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Type (2017-2022)

Figure Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Type (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Type (2017-2022)

Figure Japan Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Type in 2017

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Type in 2017

Table Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)

Figure Japan Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application (2017-2022)

Figure Japan Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application in 2017

Table Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Application (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Market Share Forecast by Application in 2017

Table Japan Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)

Table Japan Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)

Figure Japan Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)

Table Global Antitumor Drugs of Antimetabolite Class Sales () Forecast by Regions (2017-2022)

Table Global Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)

Figure Global Antitumor Drugs of Antimetabolite Class Sales Volume Share Forecast by Regions (2017-2022)

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

I would like to order

Product name: 2017-2022 Global and Japan Antitumor Drugs of Antimetabolite Class Market Analysis Report

Product link: <https://marketpublishers.com/r/2A8452B83F2EN.html>

Price: US\$ 3,085.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2A8452B83F2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

